Brokerages Set IQVIA Holdings Inc. (NYSE:IQV) Price Target at $226.32

Shares of IQVIA Holdings Inc. (NYSE:IQV - Get Free Report) have earned a consensus rating of "Moderate Buy" from the twenty-four brokerages that are currently covering the company, Marketbeat Ratings reports. Seven research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $226.32.

Several brokerages recently commented on IQV. Royal Bank of Canada restated an "outperform" rating and set a $270.00 target price on shares of IQVIA in a research report on Monday, February 10th. Stifel Nicolaus dropped their price target on IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Mizuho reduced their price objective on shares of IQVIA from $210.00 to $190.00 and set an "outperform" rating for the company in a research report on Thursday, May 15th. JPMorgan Chase & Co. dropped their target price on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a research report on Monday, May 19th. Finally, UBS Group reduced their price target on shares of IQVIA from $255.00 to $185.00 and set a "buy" rating for the company in a report on Wednesday, May 7th.

IQVIA Trading Up 3.5%

NYSE:IQV traded up $5.02 on Friday, reaching $147.80. 2,684,601 shares of the stock traded hands, compared to its average volume of 1,583,583. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA has a 1-year low of $134.65 and a 1-year high of $252.88. The company's 50 day moving average is $148.65 and its 200-day moving average is $179.70. The firm has a market capitalization of $25.57 billion, a price-to-earnings ratio of 19.71, a price-to-earnings-growth ratio of 1.99 and a beta of 1.28.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.63 by $0.07. The company had revenue of $3.83 billion during the quarter, compared to analysts' expectations of $3.77 billion. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. IQVIA's revenue for the quarter was up 2.5% compared to the same quarter last year. During the same period in the prior year, the company posted $2.54 earnings per share. Equities research analysts anticipate that IQVIA will post 10.84 EPS for the current fiscal year.

Hedge Funds Weigh In On IQVIA

Several hedge funds have recently modified their holdings of IQV. Vanguard Group Inc. lifted its holdings in IQVIA by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company's stock worth $3,956,087,000 after acquiring an additional 105,504 shares during the period. Canada Pension Plan Investment Board raised its stake in shares of IQVIA by 7.3% during the 1st quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company's stock worth $810,069,000 after purchasing an additional 312,807 shares during the period. Geode Capital Management LLC boosted its holdings in shares of IQVIA by 1.9% in the 4th quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company's stock worth $818,315,000 after buying an additional 77,981 shares during the last quarter. Invesco Ltd. grew its position in IQVIA by 53.4% during the fourth quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock valued at $509,012,000 after buying an additional 902,226 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in IQVIA by 45.7% during the first quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company's stock worth $448,686,000 after buying an additional 798,534 shares during the last quarter. Institutional investors own 89.62% of the company's stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.